To hear about similar clinical trials, please enter your email below
Trial Title:
The Rechallenge of ADCs in MBC Patients
NCT ID:
NCT05571618
Condition:
Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Conditions: Keywords:
Antibody-drug conjugates
Metastatic Breast Cancer
Study type:
Observational
Overall status:
Active, not recruiting
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Drug
Intervention name:
ADC
Description:
Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease
are allowed).
Arm group label:
Group1
Summary:
To investigate the efficacy and safety of ADC rechallenge
Criteria for eligibility:
Study pop:
Patients diagnosed with breast cancer (according to ICD-10) with confirmed metastasis,
regardless of being de novo diagnosed or progressed from a non-metastatic stage.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- age > 18 years old.
- Diagnosed with Metastatic Breast Cancer.
- Patients with prior exposure to ADC (either in the adjuvant setting or metastatic
disease are allowed).
- Patients plan to or have received ADCs for the second or more time.
- Complete medical history was available.
Exclusion Criteria:
- Medical history was incomplete
Gender:
Female
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Fudan University Shanghai Cancer Center
Address:
City:
Shanghai
Zip:
200032
Country:
China
Start date:
September 1, 2022
Completion date:
March 1, 2025
Lead sponsor:
Agency:
Fudan University
Agency class:
Other
Source:
Fudan University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05571618
